二聚体抗癌前药的最新进展综述。

IF 3.2 4区 医学 Q3 CHEMISTRY, MEDICINAL
Future medicinal chemistry Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI:10.1080/17568919.2025.2463884
Zhila Imani, Ebrahim Saeedian Moghadam, Zahra Imani, Mohsen Amini, Fatemeh Atyabi, Rassoul Dinarvand
{"title":"二聚体抗癌前药的最新进展综述。","authors":"Zhila Imani, Ebrahim Saeedian Moghadam, Zahra Imani, Mohsen Amini, Fatemeh Atyabi, Rassoul Dinarvand","doi":"10.1080/17568919.2025.2463884","DOIUrl":null,"url":null,"abstract":"<p><p>The advancement of targeted drug delivery systems has opened up a wide array of opportunities in cancer therapy, leading to the exploration of various strategies. Among these, the use of prodrugs stands out as a particularly promising approach in targeted cancer treatment, aimed at enhancing the selectivity and effectiveness of cytotoxic agents. In the last few years, there has been considerable progress in the area of dimeric-based prodrugs aimed at cancer therapy. The advantages presented by dimeric-based prodrugs have significantly improved the efficiency of delivering anticancer drugs, characterized by a high drug loading capacity, advantageous pharmacokinetics, and drug release that responds to tumor stimuli. With respect to the importance of drug dimerization in the field of prodrug development, herein we review the latest reports covering research in dimeric prodrugs. We have categorized the article according to the reported anticancer agents. We have also spent a great deal of attention on different types of used linkers and methods of the dissociation of dimeric prodrugs into free monomeric drugs. Readers will easily be able to compare between the reported research using the same drugs with different linkers or different dissociation methods as well as different cancer cell lines targeted in the studies.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"709-723"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938984/pdf/","citationCount":"0","resultStr":"{\"title\":\"A comprehensive review on the latest advances of dimeric anticancer prodrugs.\",\"authors\":\"Zhila Imani, Ebrahim Saeedian Moghadam, Zahra Imani, Mohsen Amini, Fatemeh Atyabi, Rassoul Dinarvand\",\"doi\":\"10.1080/17568919.2025.2463884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The advancement of targeted drug delivery systems has opened up a wide array of opportunities in cancer therapy, leading to the exploration of various strategies. Among these, the use of prodrugs stands out as a particularly promising approach in targeted cancer treatment, aimed at enhancing the selectivity and effectiveness of cytotoxic agents. In the last few years, there has been considerable progress in the area of dimeric-based prodrugs aimed at cancer therapy. The advantages presented by dimeric-based prodrugs have significantly improved the efficiency of delivering anticancer drugs, characterized by a high drug loading capacity, advantageous pharmacokinetics, and drug release that responds to tumor stimuli. With respect to the importance of drug dimerization in the field of prodrug development, herein we review the latest reports covering research in dimeric prodrugs. We have categorized the article according to the reported anticancer agents. We have also spent a great deal of attention on different types of used linkers and methods of the dissociation of dimeric prodrugs into free monomeric drugs. Readers will easily be able to compare between the reported research using the same drugs with different linkers or different dissociation methods as well as different cancer cell lines targeted in the studies.</p>\",\"PeriodicalId\":12475,\"journal\":{\"name\":\"Future medicinal chemistry\",\"volume\":\" \",\"pages\":\"709-723\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938984/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17568919.2025.2463884\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2025.2463884","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

靶向给药系统的进步为癌症治疗开辟了广泛的机会,导致各种策略的探索。其中,前药的使用是一种特别有前途的靶向癌症治疗方法,旨在提高细胞毒性药物的选择性和有效性。近年来,以二聚体为基础的前药在癌症治疗方面取得了长足的进展。基于二聚体的前药所表现出的优势显著提高了抗癌药物的递送效率,具有高载药量、有利的药代动力学和对肿瘤刺激响应的药物释放等特点。鉴于药物二聚体在前药开发领域的重要性,本文综述了前药二聚体研究的最新报道。我们根据报道的抗癌剂对文章进行了分类。我们也花了大量的注意力在不同类型的使用连接和二聚体前药解离成游离单体药物的方法。读者可以很容易地比较使用相同药物的不同连接体或不同解离方法的报道研究,以及研究中针对的不同癌细胞系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A comprehensive review on the latest advances of dimeric anticancer prodrugs.

The advancement of targeted drug delivery systems has opened up a wide array of opportunities in cancer therapy, leading to the exploration of various strategies. Among these, the use of prodrugs stands out as a particularly promising approach in targeted cancer treatment, aimed at enhancing the selectivity and effectiveness of cytotoxic agents. In the last few years, there has been considerable progress in the area of dimeric-based prodrugs aimed at cancer therapy. The advantages presented by dimeric-based prodrugs have significantly improved the efficiency of delivering anticancer drugs, characterized by a high drug loading capacity, advantageous pharmacokinetics, and drug release that responds to tumor stimuli. With respect to the importance of drug dimerization in the field of prodrug development, herein we review the latest reports covering research in dimeric prodrugs. We have categorized the article according to the reported anticancer agents. We have also spent a great deal of attention on different types of used linkers and methods of the dissociation of dimeric prodrugs into free monomeric drugs. Readers will easily be able to compare between the reported research using the same drugs with different linkers or different dissociation methods as well as different cancer cell lines targeted in the studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信